Indications: FDA approved: Type II diabetes - monotherapy or combination therapy Can be combined as adjunct therapy with other hypoglycemics including metformin, thiazolidinediones, or insulin regimens (Dungan & DeSantis 2015) Because it does not work when your blood sugar is low, it is unlikely to produce dangerous levels of hypoglycemia has been observed in clinical trials (in contrast to GLP-1 incretin mimetics, such as exenatide, which produce moderate weight loss)
Some may experience more significant weight loss or quicker results, while others may have a slower response
therefore, further studies are needed
PMID: 38152023 FASEB J Mitochondrial Calcium Uniporter-Mediated Regulation of the SIRT3/GSK3/-Catenin Signaling Pathway in Vascular Remodeling
Lever M, George PM, Dellow WJ, Scott RS, Chambers ST
Ipamorelin increases the synthesis of cells and it elevates the release of insulin from the pancreatic tissues